InxMed

InxMed Co., Ltd is a clinical-stage biotechnology company based in Nanjing, China, that focuses on developing innovative therapies to combat drug resistance in hard-to-treat solid tumors. The company operates in the biotechnology and healthcare market, serving clients such as hospitals, healthcare providers, and patients suffering from various types of cancer.

InxMed's primary product is Ifebemtinib (IN10018), a highly potent and selective oral inhibitor of focal adhesion kinase (FAK). This drug is designed to treat platinum-resistant recurrent ovarian cancer and triple-negative breast cancer. FAK is a protein that, when inhibited, can prevent cancer cells from growing and spreading. In addition to IN10018, InxMed is also developing IN30718, a first-in-class cancer-associated fibroblast (CAF) targeting ADC for high stroma tumors.

The company's business model revolves around the research, development, and commercialization of these innovative cancer therapies. They generate revenue through the sales of their drugs once they have been approved for use by regulatory bodies such as the China National Medical Products Administration (NMPA) and potentially the U.S. Food and Drug Administration (FDA).

InxMed recently raised $50 million in a series B funding round. The funds will be used to support clinical trials of IN-10018 in the U.S. and China, bring more stroma-targeting candidates into clinical trials, and enhance the company's research and development capabilities.

Keywords: Biotechnology, Cancer Treatment, Drug Resistance, Clinical Trials, IN10018, Focal Adhesion Kinase Inhibitor, Solid Tumors, Cancer-Associated Fibroblast, Series B Funding, Research and Development.